Mantle cell lymphoma

Critical Reviews in Oncology/Hematology

Volumn 82, Issue 1, 2012, Pages 78-101

  Cortelazzo, Sergio ^a   Ponzoni, Maurilio ^b   Ferreri, Andrés J M ^b   Dreyling, Martin ^c  

^a Azienda Ospedaliera Bolzano   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Allogeneic transplantation; B cell lymphomas; Bcl 1; Cyclin D1

Indexed keywords

BENDAMUSTINE; BORTEZOMIB; CARBOPLATIN; CARFILZOMIB; CHLORAMBUCIL; CISPLATIN; CLADRIBINE; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; FLUORODEOXYGLUCOSE F 18; GEMCITABINE; IBRITUMOMAB TIUXETAN; IFOSFAMIDE; IMMUNOGLOBULIN D; IMMUNOGLOBULIN M; KI 67 ANTIGEN; METHOTREXATE; MITOXANTRONE; PEGINTERFERON ALPHA; PREDNISONE; RITUXIMAB; SALINOSPORAMIDE A; THALIDOMIDE; TOSITUMOMAB I 131; UNINDEXED DRUG; VINCRISTINE;

ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE MARROW SUPPRESSION; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CANCER RESEARCH; CANCER STAGING; CEREBROSPINAL FLUID ANALYSIS; CHROMOSOME TRANSLOCATION 11; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DRUG POTENTIATION; DRUG TARGETING; DRUG TREATMENT FAILURE; FATIGUE; GASTROINTESTINAL ENDOSCOPY; GENE; GENE MUTATION; HEPATOMEGALY; HUMAN; IMMUNOPHENOTYPING; LYMPHADENOPATHY; MANTLE CELL LYMPHOMA; MEDICAL DECISION MAKING; META ANALYSIS (TOPIC); MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NAUSEA AND VOMITING; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; ONCOGENE MYC; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POLE2 GENE; POSITRON EMISSION TOMOGRAPHY; PROGRESSION FREE SURVIVAL; RAN GENE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REDUCED INTENSITY CONDITIONING; REVIEW; RISK FACTOR; SKIN MANIFESTATION; SLC29A2 GENE; SPLENOMEGALY; SYSTEMATIC REVIEW (TOPIC); THROMBOCYTOPENIA; THROMBOEMBOLISM; TNFRSF10B GENE; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; WALDEYER RING; WHOLE BODY RADIATION;

HUMANS; LYMPHOMA, MANTLE-CELL; NEOPLASM STAGING; PROGNOSIS;

EID: 84858798751     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2011.05.001     Document Type: Review

References (271)

1. Swerdlow S.H., Campo E., Muller-Hermelink H.K. Mantle cell lymphoma. WHO classification of tumors of haematopoietic and lymphoid tissues 2008, 229-232. IARC Press, Lyon, France. S.H. Swerdlow, E. Campo, N.L. Harris, E.S. Jaffe, S. Pileri, M. Stein, J. Thiele, J.W. Vardiman (Eds.).
2. Devesa S.S., Fears T. Non-Hodgkin's lymphoma time trends: United States and international data. Cancer Res 1992, 52:5432s-5440s.
3. Sant M., Allemani C., De Angelis R., et al. Influence of morphology on survival for non-Hodgkin lymphoma in Europe and the United States. Eur J Cancer 2008, 44:579-587.
4. Morton L.M., Wang S.S., Devesa S.S., et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006, 107:265-276.
5. Anderson J.R., Armitage J.O., Weisenburger D.D. Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project. Ann Oncol 1998, 9:717-720.
6. Pittaluga S., Tierens A., Pinyol M., et al. Blastic variant of mantle cell lymphoma shows a heterogenous pattern of somatic mutations of the rearranged immunoglobulin heavy chain variable genes. Br J Haematol 1998, 102:1301-1306.
7. Du M.Q., Diss T.C., Xu C.F., et al. Ongoing immunoglobulin gene mutations in mantle cell lymphomas. Br J Haematol 1997, 96:124-131.
8. Schollkopf C., Melbye M., Munksgaard L., et al. Borrelia infection and risk of non-Hodgkin lymphoma. Blood 2008, 111:5524-5529.
9. Weisenburger D.D. Lymphoid malignancies in Nebraska: a hypothesis. Nebraska Med J 1985, 70:300-305.
10. Zahm S.H., Weisenburger D.D., Babbitt P.A., et al. A case-control study of non-Hodgkin's lymphoma and the herbicide 2,4-dichlorophenoxyacetic acid (2,4-D) in eastern Nebraska. Epidemiology 1990, 1:349-356.
11. Woods J.S., Polissar L., Severson R.K., Heuser L.S., Kulander B.G. Soft tissue sarcoma and non-Hodgkin's lymphoma in relation to phenoxyherbicide and chlorinated phenol exposure in western Washington. J Natl Cancer Instit 1987, 78:899-910.
12. La Vecchia C., Negri E., D'Avanzo B., Franceschi S. Occupation and lymphoid neoplasms. Br J Cancer 1989, 60:385-388.
13. Scherr P.A., Hutchison G.B., Neiman R.S. Non-Hodgkin's lymphoma and occupational exposure. Cancer Res 1992, 52:5503s-5509s.
14. Muller A.M., Ihorst G., Mertelsmann R., Engelhardt M. Epidemiology of non-Hodgkin's lymphoma (NHL): trends, geographic distribution, and etiology. Ann Hematol 2005, 84:1-12.
15. Tort F., Camacho E., Bosch F., et al. Familial lymphoid neoplasms in patients with mantle cell lymphoma. Haematologica 2004, 89:314-319.
16. Duggan M.J., Weisenburger D.D., Ye Y.L., et al. Mantle zone lymphoma. A clinicopathologic study of 22 cases. Cancer 1990, 66:522-529.
17. Swerdlow S.H., Habeshaw J.A., Murray L.J., et al. Centrocytic lymphoma: a distinct clinicopathologic and immunologic entity. A multiparameter study of 18 cases at diagnosis and relapse. Am J Pathol 1983, 113:181-197.
18. Weisenburger D.D., Kim H., Rappaport H. Mantle-zone lymphoma: a follicular variant of intermediate lymphocytic lymphoma. Cancer 1982, 49:1429-1438.
19. Aqel N., Barker F., Patel K., Naresh K.N. In-situ mantle cell lymphoma-a report of two cases. Histopathology 2008, 52:256-260.
20. Orchard J., Garand R., Davis Z., et al. A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease. Blood 2003, 101:4975-4981.
21. Zukerberg L.R., Medeiros L.J., Ferry J.A., Harris N.L. Diffuse low-grade B-cell lymphomas. Four clinically distinct subtypes defined by a combination of morphologic and immunophenotypic features [see comments]. Am J Clin Pathol 1993, 100:373-385.
22. Yin C.C., Medeiros L.J., Cromwell C.C., et al. Sequence analysis proves clonal identity in five patients with typical and blastoid mantle cell lymphoma. Mod Pathol 2007, 20:1-7.
23. Argatoff L.H., Connors J.M., Klasa R.J., Horsman D.E., Gascoyne R.D. Mantle cell lymphoma: a clinicopathologic study of 80 cases. Blood 1997, 89:2067-2078.
24. Ott G., Kalla J., Ott M.M., et al. Blastoid variants of mantle cell lymphoma: frequent bcl-1 rearrangements at the major translocation cluster region and tetraploid chromosome clones. Blood 1997, 89:1421-1429.
25. Tiemann M., Schrader C., Klapper W., et al. Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network. Br J Haematol 2005, 131:29-38.
26. Katzenberger T., Petzoldt C., Holler S., et al. The Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphoma. Blood 2006, 107:3407.
27. Pinyol M., Hernandez L., Cazorla M., et al. Deletions and loss of expression of p16INK4a and p21Waf1 genes are associated with aggressive variants of mantle cell lymphomas. Blood 1997, 89:272-280.
28. Arber D.A., Rappaport H., Weiss L.M. Non-Hodgkin's lymphoproliferative disorders involving the spleen. Mod Pathol 1997, 10:18-32.
29. Hollema H., Visser L., Poppema S. Small lymphocytic lymphomas with predominant splenomegaly: a comparison of immunophenotypes with cases of predominant lymphadenopathy. Mod Pathol 1991, 4:712-717.
30. Schenka A.A., Gascoyne R.D., Duchayne E., Delsol G., Brousset P. Prominent intrasinusoidal infiltration of the bone marrow by mantle cell lymphoma. Hum Pathol 2003, 34:789-791.
31. Chan J.K. Gastrointestinal lymphomas: an overview with emphasis on new findings and diagnostic problems. Semin Diagn Pathol 1996, 13:260-296.
32. Kumar S., Krenacs L., Otsuki T., et al. bc1-1 rearrangement and cyclin D1 protein expression in multiple lymphomatous polyposis. Am J Clin Pathol 1996, 105:737-743.
33. Moynihan M.J., Bast M.A., Chan W.C., et al. Lymphomatous polyposis. A neoplasm of either follicular mantle or germinal center cell origin. Am J Surg Pathol 1996, 20:442-452.
34. Ruskone-Fourmestraux A., Delmer A., Lavergne A., et al. Multiple lymphomatous polyposis of the gastrointestinal tract: prospective clinicopathologic study of 31 cases. Groupe D'etude des Lymphomes Digestifs. Gastroenterology 1997, 112:7-16.
35. Gao J., Peterson L., Nelson B., Goolsby C., Chen Y.H. Immunophenotypic variations in mantle cell lymphoma. Am J Clin Pathol 2009, 132:699-706.
36. Gualco G., Weiss L.M., Harrington W.J., Bacchi C.E. BCL6, MUM1, and CD10 expression in mantle cell lymphoma. Appl Immunohistochem Mol Morphol 2010, 18:103-108.
37. Nanba K., Jaffe E.S., Braylan R.C., Soban E.J., Berard C.W. Alkaline phosphatase-positive malignant lymphoma. A subtype of B-cell lymphomas. Am J Clin Pathol 1977, 68:535-542.
38. Dictor M., Ek S., Sundberg M., et al. Strong lymphoid nuclear expression of SOX11 transcription factor defines lymphoblastic neoplasms, mantle cell lymphoma and Burkitt's lymphoma. Haematologica 2009, 94:1563-1568.
39. Mozos A., Royo C., Hartmann E., et al. SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. Haematologica 2009, 94:1555-1562.
40. Walsh S.H., Rosenquist R. Immunoglobulin gene analysis of mature B-cell malignancies: reconsideration of cellular origin and potential antigen involvement in pathogenesis. Med Oncol 2005, 22:327-341.
41. Kienle D., Krober A., Katzenberger T., et al. VH mutation status and VDJ rearrangement structure in mantle cell lymphoma: correlation with genomic aberrations, clinical characteristics, and outcome. Blood 2003, 102:3003-3009.
42. Bertoni F., Conconi A., Cogliatti S.B., et al. Immunoglobulin heavy chain genes somatic hypermutations and chromosome 11q22-23 deletion in classic mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research. Br J Haematol 2004, 124:289-298.
43. Cogliatti S.B., Bertoni F., Zimmermann D.R., et al. IgV H mutations in blastoid mantle cell lymphoma characterize a subgroup with a tendency to more favourable clinical outcome. J Pathol 2005, 206:320-327.
44. Fernandez V., Salamero O., Espinet B., et al. Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res 2010, 70:1408-1418.
45. Thelander E.F., Walsh S.H., Thorselius M., et al. Mantle cell lymphomas with clonal immunoglobulin V(H)3-21 gene rearrangements exhibit fewer genomic imbalances than mantle cell lymphomas utilizing other immunoglobulin V(H) genes. Mod Pathol 2005, 18:331-339.
46. Vaandrager J.W., Schuuring E., Zwikstra E., et al. Direct visualization of dispersed 11q13 chromosomal translocations in mantle cell lymphoma by multicolor DNA fiber fluorescence in situ hybridization. Blood 1996, 88:1177-1182.
47. Bertoni F., Ponzoni M. The cellular origin of mantle cell lymphoma. Int J Biochem Cell Biol 2007, 39:1747-1753.
48. Seto M., Yamamoto K., Iida S., et al. Gene rearrangement and overexpression of PRAD1 in lymphoid malignancy with t(11;14)(q13;q32) translocation. Oncogene 1992, 7:1401-1406.
49. Ott M.M., Ott G., Kuse R., et al. The anaplastic variant of centrocytic lymphoma is marked by frequent rearrangements of the bcl-1 gene and high proliferation indices. Histopathology 1994, 24:329-334.
50. Athan E., Foitl D.R., Knowles D.M. bcl-1 rearrangement. Frequency and clinical significance among B-cell chronic lymphocytic leukemias and non-Hodgkin's lymphomas. Am J Pathol 1991, 138:591-599.
51. Medeiros L.J., van Krieken J.H., Jaffe E.S., Raffeld M. Association of bcl-1 rearrangements with lymphocytic lymphoma of intermediate differentiation. Blood 1990, 76:2086-2090.
52. Vandenberghe E., De Wolf-Peeters C., van den Oord J., et al. Translocation (11;14): a cytogenetic anomaly associated with B-cell lymphomas of non-follicle centre cell lineage. J Pathol 1991, 163:13-18.
53. Rosenberg C.L., Wong E., Petty E.M., et al. PRAD1, a candidate BCL1 oncogene: mapping and expression in centrocytic lymphoma. Proc Natl Acad Sci U S A 1991, 88:9638-9642.
54. Williams M.E., Swerdlow S.H., Rosenberg C.L., Arnold A. Characterization of chromosome 11 translocation breakpoints at the bcl-1 and PRAD1 loci in centrocytic lymphoma. Cancer Res 1992, 52:5541s-5544s.
55. Harbour J.W., Dean D.C. The Rb/E2F pathway: expanding roles and emerging paradigms. Genes Dev 2000, 14:2393-2409.
56. Quintanilla-Martinez L., vies-Hill T., Fend F., et al. Sequestration of p27Kip1 protein by cyclin D1 in typical and blastic variants of mantle cell lymphoma (MCL): implications for pathogenesis. Blood 2003, 101:3181-3187.
57. Jiang W., Kahn S.M., Zhou P., et al. Overexpression of cyclin D1 in rat fibroblasts causes abnormalities in growth control, cell cycle progression and gene expression. Oncogene 1993, 8:3447-3457.
58. Bodrug S.E., Warner B.J., Bath M.L., et al. Cyclin D1 transgene impedes lymphocyte maturation and collaborates in lymphomagenesis with the myc gene. EMBO J 1994, 13:2124-2130.
59. Rosenwald A., Wright G., Wiestner A., et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 2003, 3:185-197.
60. Wlodarska I., Dierickx D., Vanhentenrijk V., et al. Translocations targeting CCND2, CCND3, and MYCN do occur in t(11;14)-negative mantle cell lymphomas. Blood 2008, 111:5683-5690.
61. Fu K., Weisenburger D.D., Greiner T.C., et al. Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. Blood 2005, 106:4315-4321.
62. Gesk S., Klapper W., Martin-Subero J.I., et al. A chromosomal translocation in cyclin D1-negative/cyclin D2-positive mantle cell lymphoma fuses the CCND2 gene to the IGK locus. Blood 2006, 108:1109-1110.
63. Salaverria I., Zettl A., Bea S., et al. Specific secondary genetic alterations in mantle cell lymphoma provide prognostic information independent of the gene expression-based proliferation signature. J Clin Oncol 2007, 25:1216-1222.
64. Greiner T.C., Moynihan M.J., Chan W.C., et al. p53 mutations in mantle cell lymphoma are associated with variant cytology and predict a poor prognosis. Blood 1996, 87:4302-4310.
65. Greiner T.C., Dasgupta C., Ho V.V., et al. Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma. PNAS 2006, 103:2352-2357.
66. Stilgenbauer S., Winkler D., Ott G., et al. Molecular characterization of 11q deletions points to a pathogenic role of the ATM gene in mantle cell lymphoma. Blood 1999, 94:3262-3264.
67. Gelebart P., Anand M., Armanious H., et al. Constitutive activation of the Wnt canonical pathway in mantle cell lymphoma. Blood 2008, 112:5171-5179.
68. Staudt L.M. Molecular diagnosis of the hematologic cancers. N Engl J Med 2003, 348:1777-1785.
69. Hernandez L., Bea S., Pinyol M., et al. CDK4 and MDM2 gene alterations mainly occur in highly proliferative and aggressive mantle cell lymphomas with wild-type INK4a/ARF locus. Cancer Res 2005, 65:2199-2206.
70. Pinyol M., Bea S., Pla L., et al. Inactivation of RB1 in mantle-cell lymphoma detected by nonsense-mediated mRNA decay pathway inhibition and microarray analysis. Blood 2007, 109:5422-5429.
71. Dreyling M.H., Bullinger L., Ott G., et al. Alterations of the cyclin D1/p16-pRB pathway in mantle cell lymphoma. Cancer Res 1997, 57:4608-4614.
72. Rudelius M., Pittaluga S., Nishizuka S., et al. Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma. Blood 2006, 108:1668-1676.
73. Dal C.J., Zancai P., Terrin L., et al. Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma. Blood 2008, 111:5142-5151.
74. Pérez-Galán P., Dreyling M., Wiestner A. Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood 2011, 117((January) 1):26-38. [Epub 2010 Oct 12. Review].
75. Shor B., Gibbons J.J., Abraham R.T., et al. Targeting mTOR globally in cancer: thinking beyond rapamycin. Cell Cycle 2009, 8(December (23)):3831-3837. [Epub 2009 Dec 14].
76. Haritunians T., Mori A., O'Kelly J., et al. Antiproliferative activity of RAD001 (everolimus) as a single agent and combined with other agents in mantle cell lymphoma. Leukemia 2007, 21(February (2)):333-339. [Epub 2006 Nov 30].
77. Witzig T.E. Current treatment approaches for mantle-cell lymphoma. J Clin Oncol 2005, 23(September (26)):6409-6414. [Review].
78. Younes A. Therapeutic activity of mTOR inhibitors in mantle cell lymphoma: clues but no clear answers. Autophagy 2008, 4(July (5)):707-709. [Epub 2008 May 6, Review].
79. Dal Col J., Zancai P., Terrin L., et al. Distinct functional significance of Akt and mTOR constitutive activation in mantle cell lymphoma. Blood 2008, 111(May (10)):5142-5151. [Epub 2008 Mar 13].
80. Camacho E., Hernandez L., Hernandez S., et al. ATM gene inactivation in mantle cell lymphoma mainly occurs by truncating mutations and missense mutations involving the phosphatidylinositol-3 kinase domain and is associated with increasing numbers of chromosomal imbalances. Blood 2002, 99:238-244.
81. Bosch F., Lopez-Guillermo A., Campo E., et al. Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors. Cancer 1998, 82:567-575.
82. Velders G.A., Kluin-Nelemans J.C., de Boer C.J., et al. Mantle-cell lymphoma: a population-based clinical study. J Clin Oncol 1996, 14:1269-1274.
83. Fisher R.I. Mantle-cell lymphoma: classification and therapeutic implications. Ann Oncol 1996, 7(Suppl. 6). S35-9.
84. Zucca E., Stein H., Coiffier B. European Lymphoma Task Force (ELTF): report of the workshop on Mantle Cell Lymphoma (MCL) [see comments]. Ann Oncol 1994, 5:507-511.
85. Ferrer A., Bosch F., Villamor N., et al. Central nervous system involvement in mantle cell lymphoma. Ann Oncol 2008, 19:135-141.
86. Gill S., Herbert K.E., Prince H.M., et al. Mantle cell lymphoma with central nervous system involvement: frequency and clinical features. Br J Haematol 2009, 147:83-88.
87. Cohen P.L., Kurtin P.J., Donovan K.A., Hanson C.A. Bone marrow and peripheral blood involvement in mantle cell lymphoma. Br J Haematol 1998, 101:302-310.
88. Pittaluga S., Verhoef G., Criel A., et al. Prognostic significance of bone marrow trephine and peripheral blood smears in 55 patients with mantle cell lymphoma. Leuk Lymphoma 1996, 21:115-125.
89. De Oliveira M.S., Jaffe E.S., Catovsky D. Leukaemic phase of mantle zone (intermediate) lymphoma: its characterisation in 11 cases [see comments]. J Clin Pathol 1989, 42:962-972.
90. Ferrer A., Salaverria I., Bosch F., et al. Leukemic involvement is a common feature in mantle cell lymphoma. Cancer 2007, 109:2473-2480.
91. Bottcher S., Ritgen M., Buske S., et al. Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations. Haematologica 2008, 93:551-559.
92. Viswanatha D.S., Foucar K., Berry B.R., et al. Blastic mantle cell leukemia: an unusual presentation of blastic mantle cell lymphoma. Mod Pathol 2000, 13:825-833.
93. Samaha H., Dumontet C., Ketterer N., et al. Mantle cell lymphoma: a retrospective study of 121 cases. Leukemia 1998, 12:1281-1287.
94. Preud'homme J.L., Gombert J., Brizard A., et al. Serum Ig abnormalities in mantle cell lymphoma [letter; comment]. Blood 1997, 90:894-896.
95. Romaguera J.E., Medeiros L.J., Hagemeister F.B., et al. Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma. Cancer 2003, 97:586-591.
96. O'Briain D.S., Kennedy M.J., Daly P.A., et al. Multiple lymphomatous polyposis of the gastrointestinal tract. A clinicopathologically distinctive form of non-Hodgkin's lymphoma of B-cell centrocytic type. Am J Surg Pathol 1989, 13:691-699.
97. Brepoels L., Stroobants S., De W.W., et al. Positron emission tomography in mantle cell lymphoma. Leuk Lymphoma 2008, 49:1693-1701.
98. Cheson B.D., Pfistner B., Juweid M.E., et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007, 25:579-586.
99. Gill S., Wolf M., Prince H.M., et al. [18F]fluorodeoxyglucose positron emission tomography scanning for staging, response assessment, and disease surveillance in patients with mantle cell lymphoma. Clin Lymphoma Myeloma 2008, 8:159-165.
100. Han H.S., Escalon M.P., Hsiao B., Serafini A., Lossos I.S. High incidence of false-positive PET scans in patients with aggressive non-Hodgkin's lymphoma treated with rituximab-containing regimens. Ann Oncol 2009, 20:309-318.
101. Bertoni F., Roggero E., Luscieti P., et al. Clonality assessment in blood of patients with mantle cell lymphoma [In Process Citation]. Leuk Lymphoma 1999, 32:375-379.
102. Carbone P.P., Kaplan H.S., Musshoff K., Smithers D.W., Tubiana M. Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res 1971, 31:1860-1861.
103. Andersen N.S., Donovan J.W., Borus J.S., et al. Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease. Blood 1997, 90:4212-4221.
104. Corradini P., Astolfi M., Cherasco C., et al. Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting. Blood 1997, 89:724-731.
105. Gribben J.G., Freedman A., Woo S.D., et al. All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment. Blood 1991, 78:3275-3280.
106. Lin F., Cross N.C. Molecular methods for monitoring malignant disease after bone marrow transplantation. Curr Opin Hematol 1995, 2:460-467.
107. Gribben J.G., Neuberg D., Barber M., et al. Detection of residual lymphoma cells by polymerase chain reaction in peripheral blood is significantly less predictive for relapse than detection in bone marrow. Blood 1994, 83:3800-3807.
108. Magni M., Di N.M., Devizzi L., et al. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. Blood 2000, 96:864-869.
109. Alt F.W., Blackwell T.K., Yancopoulos G.D. Development of the primary antibody repertoire. Science 1987, 238:1079-1087.
110. Andersen N.S., Donovan J.W., Zuckerman A., et al. Real-time polymerase chain reaction estimation of bone marrow tumor burden using clonal immunoglobulin heavy chain gene and bcl-1/JH rearrangements in mantle cell lymphoma. Exp Hematol 2002, 30:703-710.
111. Howard O.M., Gribben J.G., Neuberg D.S., et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol 2002, 20:1288-1294.
112. Kahl B.S., Longo W.L., Eickhoff J.C., et al. Maintenance rituximab following induction chemoimmunotherapy may prolong progression-free survival in mantle cell lymphoma: a pilot study from the Wisconsin Oncology Network. Ann Oncol 2006, 17:1418-1423.
113. Pott C., Schrader C., Gesk S., et al. Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma. Blood 2006, 107:2271-2278.
114. Pott C., Hoster E., fau-Larue M.H., et al. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. Blood 2010, 115:3215-3223.
115. Ladetto M., Magni M., Pagliano G., et al. Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma. Biol Blood Marrow Transplant 2006, 12:1270-1276.
116. Andersen N.S., Pedersen L.B., Laurell A., et al. Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma. J Clin Oncol 2009, 27:4365-4370.
117. Norton A.J., Matthews J., Pappa V., et al. Mantle cell lymphoma: natural history defined in a serially biopsied population over a 20-year period. Ann Oncol 1995, 6:249-256.
118. Zucca E., Roggero E., Pinotti G., et al. Patterns of survival in mantle cell lymphoma. Ann Oncol 1995, 6:257-262.
119. Hiddemann W., Unterhalt M., Herrmann R., et al. Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group. J Clin Oncol 1998, 16:1922-1930.
120. Lardelli P., Bookman M.A., Sundeen J., Longo D.L., Jaffe E.S. Lymphocytic lymphoma of intermediate differentiation. Morphologic and immunophenotypic spectrum and clinical correlations. Am J Surg Pathol 1990, 14:752-763.
121. Herrmann A., Hoster E., Zwingers T., et al. Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol 2009, 27:511-518.
122. Martin P., Chadburn A., Christos P., et al. Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol 2009, 27:1209-1213.
123. Meusers P., Engelhard M., Bartels H., et al. Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: anthracycline does not improve the prognosis. Hematol Oncol 1989, 7:365-380.
124. Callea V., Clo V., Morabito F., et al. Retrospective analysis of mantle cell lymphoma: experience of the " Gruppo Italiano per lo Studio dei Linfomi" (GISL). Haematologica 1998, 83:993-997.
125. Montserrat E., Bosch F., Lopez-Guillermo A., et al. CNS involvement in mantle-cell lymphoma. J Clin Oncol 1996, 14:941-944.
126. Oinonen R., Franssila K., Elonen E. Central nervous system involvement in patients with mantle cell lymphoma [In Process Citation]. Ann Hematol 1999, 78:145-149.
127. Raty R., Franssila K., Jansson S.E., et al. Predictive factors for blastoid transformation in the common variant of mantle cell lymphoma. Eur J Cancer 2003, 39:321-329.
128. Decaudin D., Bosq J., Munck J.N., et al. Mantle cell lymphomas: characteristics, natural history and prognostic factors of 45 cases. Leuk Lymphoma 1997, 26:539-550.
129. Fisher R.I., Dahlberg S., Nathwani B.N., et al. A clinical analysis of two indolent lymphoma entities: mantle cell lymphoma and marginal zone lymphoma (including the mucosa-associated lymphoid tissue and monocytoid B-cell subcategories): a Southwest Oncology Group study. Blood 1995, 85:1075-1082.
130. Pittaluga S., Wlodarska I., Stul M.S., et al. Mantle cell lymphoma: a clinicopathological study of 55 cases. Histopathology 1995, 26:17-24.
131. Andersen N.S., Jensen M.K., de Nully B.P., Geisler C.H. A Danish population-based analysis of 105 mantle cell lymphoma patients: incidences, clinical features, response, survival and prognostic factors. Eur J Cancer 2002, 38:401-408.
132. Khouri I.F., Saliba R.M., Okoroji G.J., Acholonu S.A., Champlin R.E. Long-term follow-up of autologous stem cell transplantation in patients with diffuse mantle cell lymphoma in first disease remission: the prognostic value of beta2-microglobulin and the tumor score. Cancer 2003, 98:2630-2635.
133. Solal-Celigny P., Roy P., Colombat P., et al. Follicular lymphoma international prognostic index. Blood 2004, 104:1258-1265.
134. Moller M.B., Pedersen N.T., Christensen B.E. Mantle cell lymphoma: prognostic capacity of the Follicular Lymphoma International Prognostic Index. Br J Haematol 2006, 133:43-49.
135. Hoster E., Dreyling M., Klapper W., et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008, 111:558-565.
136. Shah J.J., Fayad L., Romaguera J. Mantle cell international prognostic index (MIPI) not prognostic after R-hyper-CVAD. Blood 2008, 112:2583-2584.
137. Hoster E., Hasford J., Hermine O., et al. Confirmation of the mantle cell lymphoma international prognostic index (MIPI) in an independent prospective patient cohort. ASH Annual Meet Abstr 2009, 114:138.
138. Geisler C.H., Kolstad A., Laurell A., et al. The Mantle Cell Lymphoma International Prognostic Index (MIPI) is superior to the International Prognostic Index (IPI) in predicting survival following intensive first-line immunochemotherapy and autologous stem cell transplantation (ASCT). Blood 2010, 115:1530-1533.
139. de Jong D., Rosenwald A., Chhanabhai M., et al. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications-a study from the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol 2007, 25:805-812.
140. Klapper W., Hoster E., Determann O., et al. Ki-67 as a prognostic marker in mantle cell lymphoma-consensus guidelines of the pathology panel of the European MCL Network. J Hematop 2009.
141. Bea S., Ribas M., Hernandez J.M., et al. Increased number of chromosomal imbalances and high-level DNA amplifications in mantle cell lymphoma are associated with blastoid variants. Blood 1999, 93:4365-4374.
142. Allen J.E., Hough R.E., Goepel J.R., et al. Identification of novel regions of amplification and deletion within mantle cell lymphoma DNA by comparative genomic hybridization. Br J Haematol 2002, 116:291-298.
143. Rubio-Moscardo F., Climent J., Siebert R., et al. Mantle-cell lymphoma genotypes identified with CGH to BAC microarrays define a leukemic subgroup of disease and predict patient outcome. Blood 2005, 105:4445-4454.
144. Flordal T.E., Ichimura K., Collins V.P., et al. Detailed assessment of copy number alterations revealing homozygous deletions in 1p and 13q in mantle cell lymphoma. Leuk Res 2007, 31:1219-1230.
145. Hernandez L., Fest T., Cazorla M., et al. p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas. Blood 1996, 87:3351-3359.
146. Pinyol M., Hernandez L., Martinez A., et al. INK4a/ARF locus alterations in human non-Hodgkin's lymphomas mainly occur in tumors with wild-type p53 gene. Am J Pathol 2000, 156:1987-1996.
147. Kienle D., Katzenberger T., Ott G., et al. Quantitative gene expression deregulation in mantle-cell lymphoma: correlation with clinical and biologic factors. J Clin Oncol 2007, 25:2770-2777.
148. Hartmann E., Fernandez V., Moreno V., et al. Five-gene model to predict survival in mantle-cell lymphoma using frozen or formalin-fixed, paraffin-embedded tissue. J Clin Oncol 2008, 26:4966-4972.
149. Leitch H.A., Gascoyne R.D., Chhanabhai M., et al. Limited-stage mantle-cell lymphoma. Ann Oncol 2003, 14:1555-1561.
150. Vandenberghe E., De Wolf-Peeters C., Vaughan H.G., et al. The clinical outcome of 65 cases of mantle cell lymphoma initially treated with non-intensive therapy by the British National Lymphoma Investigation Group. Br J Haematol 1997, 99:842-847.
151. Rosenbluth B.D., Yahalom J. Highly effective local control and palliation of mantle cell lymphoma with involved-field radiation therapy (IFRT). Int J Radiat Oncol Biol Phys 2006, 65:1185-1191.
152. Determann O., Hoster E., Ott G., et al. Ki-67 predicts outcome in advanced-stage mantle cell lymphoma patients treated with anti-CD20 immunochemotherapy: results from randomized trials of the European MCL Network and the German Low Grade Lymphoma Study Group. Blood 2008, 111:2385-2387.
153. Schulz H., Bohlius J.F., Trelle S., et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 2007, 99:706-714.
154. Matutes E., Parry-Jones N., Brito-Babapulle V., et al. The leukemic presentation of mantle-cell lymphoma: disease features and prognostic factors in 58 patients. Leuk Lymphoma 2004, 45:2007-2015.
155. Yoong Y., Kurtin P.J., Allmer C., et al. Efficacy of splenectomy for patients with mantle cell non-Hodgkin's lymphoma. Leuk Lymphoma 2001, 42:1235-1241.
156. Barista I., Romaguera J.E., Cabanillas F. Mantle-cell lymphoma. Lancet Oncol 2001, 2:141-148.
157. Teodorovic I., Pittaluga S., Kluin-Nelemans J.C., et al. Efficacy of four different regimens in 64 mantle-cell lymphoma cases: clinicopathologic comparison with 498 other non-Hodgkin's lymphoma subtypes. European Organization for the Research and Treatment of Cancer Lymphoma Cooperative Group. J Clin Oncol 1995, 13:2819-2826.
158. Nickenig C., Dreyling M., Hoster E., et al. Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group. Cancer 2006, 107:1014-1022.
159. Lenz G., Hiddemann W., Dreyling M. The role of fludarabine in the treatment of follicular and mantle cell lymphoma. Cancer 2004, 101:883-893.
160. Inwards D.J., Fishkin P.A., Hillman D.W., et al. Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group. Cancer 2008, 113:108-116.
161. Rummel M.J., Chow K.U., Karakas T., et al. Reduced-dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle-cell and low-grade non-Hodgkin's lymphoma. Eur J Cancer 2002, 38:1739-1746.
162. Jacobsen E., Freedman A. An update on the role of high-dose therapy with autologous or allogeneic stem cell transplantation in mantle cell lymphoma. Curr Opin Oncol 2004, 16:106-113.
163. Vandenberghe E., Ruiz de E.C., Loberiza F.R., et al. Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries. Br J Haematol 2003, 120:793-800.
164. Lefrere F., Delmer A., Suzan F., et al. Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study. Leukemia 2002, 16:587-593.
165. Lefrere F., Delmer A., Levy V., et al. Sequential chemotherapy regimens followed by high-dose therapy with stem cell transplantation in mantle cell lymphoma: an update of a prospective study. Haematologica 2004, 89:1275-1276.
166. Ganti A.K., Bierman P.J., Lynch J.C., et al. Hematopoietic stem cell transplantation in mantle cell lymphoma. Ann Oncol 2005, 16:618-624.
167. Evens A.M., Winter J.N., Hou N., et al. A phase II clinical trial of intensive chemotherapy followed by consolidative stem cell transplant: long-term follow-up in newly diagnosed mantle cell lymphoma. Br J Haematol 2008, 140:385-393.
168. Khouri I.F., Romaguera J., Kantarjian H., et al. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J Clin Oncol 1998, 16:3803-3809.
169. Dreyling M., Lenz G., Hoster E., et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 2005, 105:2677-2684.
170. Dreyling M.H., Hoster E., Van Hoof A., et al. Early Consolidation with Myeloablative Radiochemotherapy Followed by Autologous Stem Cell Transplantation in First Remission in Mantle Cell Lymphoma: Long Term Follow up of a Randomized Trial of the. ASH Annual Meet Abstr 2008, 112:769.
171. Freedman A.S., Neuberg D., Gribben J.G., et al. High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission [see comments]. J Clin Oncol 1998, 16:13-18.
172. Tworek J.A., Singleton T.P., Schnitzer B., Hsi E.D., Ross C.W. Flow cytometric and immunohistochemical analysis of small lymphocytic lymphoma, mantle cell lymphoma, and plasmacytoid small lymphocytic lymphoma. Am J Clin Pathol 1998, 110:582-589.
173. Ghielmini M., Schmitz S.F., Cogliatti S., et al. Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 2005, 23:705-711.
174. Coiffier B., Haioun C., Ketterer N., et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998, 92:1927-1932.
175. Foran J.M., Rohatiner A.Z., Cunningham D., et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 2000, 18:317-324.
176. Grillo-Lopez A.J. Is rituximab effective as a single agent in mantle-cell lymphoma?. Nat Clin Pract Oncol 2005, 2:500-501.
177. Lenz G., Dreyling M., Hoster E., et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005, 23:1984-1992.
178. Hoster E., Unterhalt M., Wormann B., et al. The addition of rituximab to first-line chemotherapy (R-CHOP) results in superior response rates, time to treatment failure and response duration in patients with advanced stage mantle cell lymphoma: long term results of a randomized GLSG trial. ASH Annual Meet Abstr 2008, 112:3049.
179. Herold M., Haas A., Doerken B., et al. Immunochemotherapy (RMCP) in advanced mantle cell lymphoma is not superior to chemotherapy (MCP) alone. 50 months up date of the OSHO phase III study (OSHO# 39). Ann Oncol 2008, 19:12.
180. Forstpointner R., Unterhalt M., Dreyling M., et al. Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 2006, 108:4003-4008.
181. Hoster E, Unterhalt M, Wormann B, et al., on behalf of the German Low-Grade Lymphoma Study Group (GLSG) and the European MCL Network. The addition of Rituximab to First-Line Chemotherapy (R-CHOP) results in superior response rates, time to treatment failure and response duration in patients with advanced stage mantle cell lymphoma-long-term results of a GLSG trial. Oncology 2009;32(October (S4)):#V562.
182. Inwards D.J., Hillman D.W., Fishkin P.A., et al. Phase II study of rituximab and cladribine (2-CDA) in newly diagnosed mantle cell lymphoma (MCL) (N0189). ASH Annual Meet Abstr 2006, 108:2746.
183. Dreyling M, Hoster E, Hermine O, et al. European mantle cell lymphoma network: an update on current first line trials. Ann Oncol 2008;19(Suppl. 4):#300.
184. Bauwens D., Maerevoet M., Michaux L., et al. Activity and safety of combined rituximab with chlorambucil in patients with mantle cell lymphoma. Br J Haematol 2005, 131:338-340.
185. Cheson B.D., Rummel M.J. Bendamustine: rebirth of an old drug. J Clin Oncol 2009, 27:1492-1501.
186. Rummel M.J., Al-Batran S.E., Kim S.Z., et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol 2005, 23:3383-3389.
187. Weide R., Hess G., Koppler H., et al. High anti-lymphoma activity of bendamustine/mitoxantrone/rituximab in rituximab pretreated relapsed or refractory indolent lymphomas and mantle cell lymphomas. A multicenter phase II study of the German Low Grade Lymphoma Study Group (GLSG). Leuk Lymphoma 2007, 48:1299-1306.
188. Robinson K.S., Williams M.E., van der Jagt R.H., et al. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma. J Clin Oncol 2008, 26:4473-4479.
189. Rummel M.J., Niederle N., Maschmeyer G., et al. Bendamustine plus rituximab is superior in respect of progression free survival and CR rate when compared to chop plus rituximab as first-line treatment of patients with advanced follicular, indolent, and mantle cell lymphomas: final results of a randomized phase III Study of the StiL (Study Group Indolent Lymphomas, Germany). ASH Annual Meet Abstr 2009, 114:405.
190. Romaguera J.E., Fayad L., Rodriguez M.A., et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005, 23:7013-7023.
191. Fayad L., Thomas D., Romaguera J. Update of the M. D. Anderson Cancer Center experience with hyper-CVAD and rituximab for the treatment of mantle cell and Burkitt-type lymphomas. Clin Lymphoma Myeloma 2007, 8(Suppl. 2):S57-S62. S57-S62.
192. Romaguera J., Fayad L., Rodriguez A., et al. Rituximab (R)+hypercvad alternating with r-methotrexate/cytarabine after 9 years: continued high rate of failure-free survival in untreated mantle cell lymphoma (MCL). ASH Annual Meet Abstr 2008, 112:833.
193. Epner E.M., Unger J., Miller J.B., et al. A multi center trial of hyperCVAD+Rituxan in patients with newly diagnosed mantle cell lymphoma. Blood 2007, 110. [Abstract 387].
194. Vose J., Loberiza F., Bierman P., Bociek G., Armitage J. Mantle cell lymphoma (MCL): induction therapy with hyperCVAD/high-dose methotrexate and cytarabine (M-C) (±rituximab) improves results of autologous stem cell transplant in first remission. J Clin Oncol. J Clin Oncol 2006, 24:7511.
195. Gianni A.M., Magni M., Martelli M., et al. Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). Blood 2003, 102:749-755.
196. Magni M., Di N.M., Carlo-Stella C., et al. High-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting in mantle cell lymphoma: a 10-year update of the R-HDS regimen. Bone Marrow Transplant 2009, 43:509-511.
197. Cortelazzo S., Magni M., Tarella C., et al. Update of a GITIL cohort study: frontline high dose sequential chemotherapy with rituximab and autologous stem cell transplantation induces a high rate of long-term remissions in patients with mantle cell lymphoma. ASH Annual Meet Abstr 2007, 110:1282.
198. Geisler C.H., Kolstad A., Laurell A., et al. Nordic Lymphoma Group.Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008, 112(October (7)):2687-2693. [Epub 2008 Jul 14].
199. van't Veer M.B., de Jong D., MacKenzie M., et al. High-dose Ara-C and beam with autograft rescue in R-CHOP responsive mantle cell lymphoma patients. Br J Haematol 2009, 144:524-530.
200. Thieblemont C., Antal D., Lacotte-Thierry L., et al. Chemotherapy with rituximab followed by high-dose therapy and autologous stem cell transplantation in patients with mantle cell lymphoma. Cancer 2005, 104:1434-1441.
201. de Guibert S., Jaccard A., Bernard M., et al. Rituximab and DHAP followed by intensive therapy with autologous stem-cell transplantation as first-line therapy for mantle cell lymphoma. Haematologica 2006, 91:425-426.
202. Dreger P., Laport G.G. Controversies in lymphoma: the role of hematopoietic cell transplantation for mantle cell lymphoma and peripheral T cell lymphoma. Biol Blood Marrow Transplant 2008, 14:100-107.
203. Delarue R., Haioun C., Ribrag V., et al. RCHOP and RDHAP followed by autologous stem cell transplantation (ASCT) in mantle cell lymphoma (MCL): final results of a phase II study from the GELA. ASH Annual Meet Abstr 2008, 112:581.
204. Hermine O, Hoster E, Walewski J, et al. Alternating Courses of 3x CHOP and 3x DHAP Plus Rituximab Followed by a High Dose ARA-C Containing Myeloablative Regimen and Autologous Stem Cell Transplantation (ASCT) Is Superior to 6 Courses CHOP Plus Rituximab Followed by Myeloablative Radiochemotherapy and ASCT In Mantle Cell Lymphoma: Results of the MCL Younger Trial of the European Mantle Cell Lymphoma Network. Blood 2010: abstract #110.
205. Mangel J., Leitch H.A., Connors J.M., et al. Intensive chemotherapy and autologous stem-cell transplantation plus rituximab is superior to conventional chemotherapy for newly diagnosed advanced stage mantle-cell lymphoma: a matched pair analysis. Ann Oncol 2004, 15:283-290.
206. Brugger W., Hirsch J., Grunebach F., et al. Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II study. Ann Oncol 2004, 15:1691-1698.
207. Grigg A.P., Bashford J., Seymour J.F., et al. Autografting followed by rituximab for chemosensitive mantle cell lymphoma: a pilot study and literature review. Leuk Lymphoma 2005, 46:851-860.
208. Hicks L., Connors J.M., Mangel J., et al. autologous stem-cell transplant with a rituximab purge and maintenance vs. standard chemotherapy for mantle cell lymphoma: extended follow-up of a matched pair analysis. ASH Annual Meet Abstr 2006, 108:3051.
209. Wang M., Oki Y., Pro B., et al. Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009, 27:5213-5218.
210. Weigert O., Juczak W., von Schilling C., et al. Efficacy of radioimmunotherapy with (90Y) ibritumomab tiuxetan is superior as consolidation in relapsed or refractory mantle cell lymphoma: results of two phase II trials of the European MCL network and the PLRG. J Clin Oncol 2006, 24:7533.
211. Smith M.R., Chen H., Gordon L., et al. Phase II study of rituximab+CHOP followed by 90Y-ibritumomab tiuxetan in patients with previously untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group Study (E1499). J Clin Oncol 2006, 24:7503.
212. Jurczak W., Giza A., Szostek M., et al. 90Y-Zevalin(R) (90Y-Ibritumomab Tiuxetan) radioimmunotherapy (RIT) consolidation of FCM induction chemotherapy in mantle cell lymphoma (MCL) patients: results from the PLRG upon completed enrollment. ASH Annual Meet Abstr 2006, 108:2747.
213. Zelenetz A.D., Noy A., Pandit-Taskar N., et al. Sequential radioimmunotherapy with tositumomab/Iodine I131 tositumomab followed by CHOP for mantle cell lymphoma demonstrates RIT can induce molecular remissions. J Clin Oncol 2006, 24:7560.
214. Krishnan A., Nademanee A., Fung H.C., et al. Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma. J Clin Oncol 2008, 26:90-95.
215. Gopal A.K., Rajendran J.G., Petersdorf S.H., et al. High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood 2002, 99:3158-3162.
216. Khouri I.F., Lee M.S., Romaguera J., et al. Allogeneic hematopoietic transplantation for mantle-cell lymphoma: molecular remissions and evidence of graft-versus-malignancy. Ann Oncol 1999, 10:1293-1299.
217. Tam C.S., Bassett R., Ledesma C., et al. Mature results of the M.D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma. Blood 2009, 113:4144-4152.
218. Khouri I.F., Lee M.S., Saliba R.M., et al. Nonablative allogeneic stem-cell transplantation for advanced/recurrent mantle-cell lymphoma. J Clin Oncol 2003, 21:4407-4412.
219. Maris M.B., Sandmaier B.M., Storer B.E., et al. Allogeneic hematopoietic cell transplantation after fludarabine and 2Gy total body irradiation for relapsed and refractory mantle cell lymphoma. Blood 2004, 104:3535-3542.
220. Kasamon Y.L., Jones R.J., Diehl L.F., et al. Outcomes of autologous and allogeneic blood or marrow transplantation for mantle cell lymphoma. Biol Blood Marrow Transplant 2005, 11:39-46.
221. Tsai T., Goodman S., Saez R., et al. Allogeneic bone marrow transplantation in patients who relapse after autologous transplantation. Bone Marrow Transplant 1997, 20:859-863.
222. Ringden O., Labopin M., Frassoni F., et al. Allogeneic bone marrow transplant or second autograft in patients with acute leukemia who relapse after an autograft. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant 1999, 24:389-396.
223. Milpied N., Gaillard F., Moreau P., et al. High-dose therapy with stem cell transplantation for mantle cell lymphoma: results and prognostic factors, a single center experience. Bone Marrow Transplant 1998, 22:645-650.
224. Kroger N., Hoffknecht M., Dreger P., et al. Long-term disease-free survival of patients with advanced mantle-cell lymphoma following high-dose chemotherapy. Bone Marrow Transplant 1998, 21:55-57.
225. Kroger N., Hoffknecht M., Kruger W., et al. Allogeneic bone marrow transplantation for refractory mantle cell lymphoma. Ann Hematol 2000, 79:578-580.
226. Robinson S.P., Goldstone A.H., Mackinnon S., et al. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation. Blood 2002, 100:4310-4316.
227. Avivi I., Canals C., Taghipour G., et al. Matched unrelated donor stem cell transplantation for relapsed or refractory mantle cell lymphoma. A retrospective analysis from the EBMT Lymphoma Working Party. ASH Annual Meet Abstr 2006, 108:3123.
228. Robinson S.P., Sureda A., Canals C., et al. Identification of prognostic factors predicting the outcome of reduced intensity allogeneic stem cell transplantation in mantle cell lymphoma. An Analysis from the Lymphoma Working Party of the EBMT. ASH Annual Meet Abstr 2008, 112:457.
229. Sorror M.L., Storer B., Sandmaier B.M., et al. Sustained graft-versus-lymphoma effect among patients (pts) with mantle cell lymphoma (MCL) given nonmyeloablative allogeneic hematopoietic cell transplantation (HCT). ASH Annual Meeting Abstracts 2008, 112:2147.
230. Le Gouill S., Kroeger N., Dhedin N., et al. Interest of non-myeloablative allogeneic stem cell transplantation in mantle cell lymphoma: a multicenter retrospective study. ASH Annual Meet Abstr 2008, 112:1965.
231. Corradini P., Dodero A., Farina L., et al. Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome. Leukemia 2007, 21:2316-2323.
232. Armand P., Kim H.T., Ho V.T., et al. Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome. Biol Blood Marrow Transplant 2008, 14:418-425.
233. Thomas D.W., Owen R.G., Johnson S.A., et al. Superior quality and duration of responses among patients with mantle-cell lymphoma treated with fludarabine and cyclophosphamide with or without rituximab compared with prior responses to CHOP. Leuk Lymphoma 2005, 46:549-552.
234. Forstpointner R., Dreyling M., Repp R., et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004, 104:3064-3071.
235. Mohrbacher A., Khan A.U., Tulpule A., et al. Results of a pilot trial of fludarabine, mitoxantrone and rituximab in mantle cell lymphoma. J Clin Oncol 2004, 22:6697.
236. Jermann M., Jost L.M., Taverna C., et al. Rituximab-EPOCH, an effective salvage therapy for relapsed, refractory or transformed B-cell lymphomas: results of a phase II study. Ann Oncol 2004, 15:511-516.
237. Morschhauser F., Depil S., Jourdan E., et al. Phase II study of gemcitabine-dexamethasone with or without cisplatin in relapsed or refractory mantle cell lymphoma. Ann Oncol 2007, 18:370-375.
238. Hideshima T., Ikeda H., Chauhan D., et al. Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood 2009, 114(July (5)):1046-1052. Epub 2009 May 12.
239. Yang D.T., Young K.H., Kahl B.S., Markovina S., Miyamoto S. Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma. Mol Cancer 2008, May (7):40.
240. Rizzatti E.G., Mora-Jensen H., Weniger M.A., et al. Noxa mediates bortezomib induced apoptosis in both sensitive and intrinsically resistant mantle cell lymphoma cells and this effect is independent of constitutive activity of the AKT and NF-kappaB pathways. Leuk Lymphoma 2008, 49(April (4)):798-808.
241. Pérez-Galán P., Roué G., Villamor N., et al. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status. Blood 2006, 107(January (1)):257-264. Epub 2005 Sep 15.
242. Weniger M.A. NRF2 at the interface of oxidative and endoplasmic reticulum stress pathways is a critical integrator of bortezomib response in mantle cell lymphoma in vitro and in vivo. Blood 2009, 114(22). [Abstract 727].
243. Wang Q., Mora-Jensen H., Weniger M.A., Perez-Galan P., Wolford C., Hai T., Ron D., Chen W., Trenkle W., Wiestner A., Ye Y. ERAD inhibitors integrate ER stress with an epigenetic mechanism to activate BH3-only protein NOXA in cancer cells. Proc Natl Acad Sci U S A. 2009, 106(7):2200-2205.
244. Goy A., Younes A., McLaughlin P., et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 2005, 23:667-675.
245. Goy A., Bernstein S.H., Kahl B.S., et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol 2009, 20:520-525.
246. O'Connor O.A., Wright J., Moskowitz C., et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 2005, 23:676-684.
247. Strauss S.J., Maharaj L., Hoare S., et al. Bortezomib therapy in patients with relapsed or refractory lymphoma: potential correlation of in vitro sensitivity and tumor necrosis factor alpha response with clinical activity. J Clin Oncol 2006, 24:2105-2112.
248. Fisher R.I., Bernstein S.H., Kahl B.S., et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006, 24:4867-4874.
249. Belch A., Kouroukis C.T., Crump M., et al. A phase II study of bortezomib in mantle cell lymphoma: the National Cancer Institute of Canada Clinical Trials Group trial IND.150. Ann Oncol 2007, 18:116-121.
250. Romaguera J., Fayad L., McLaughlin P., et al. Phase I trial of bortezomib in combination with rituximab-HYPERCVAD/methotrexate and cytarabine for untreated mantle cell lymphoma. ASH Annual Meet Abstr 2008, 112:3051.
251. Kahl B., Chang J., Eickhoff J., et al. VcR-CVAD produces a high complete response rate in untreated mantle cell lymphoma: a phase II study from the Wisconsin oncology network. ASH Annual Meet Abstr 2008, 112:265.
252. Weigert O., Weidmann E., Mueck R., et al. A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma-long-term results of a multicenter observation study. Leuk Lymphoma 2009, 50:716-722.
253. Weigert O., Pastore A., Rieken M., Lang N., Hiddemann W., Dreyling M. Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma. Leukemia 2007, 21(March (3)):524-528. [Epub 2007 Feb 1].
254. Chauhan D., Catley L., Li G., et al. A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell 2005, 8(November (5)):407-419.
255. O'Connor O.A., Stewart A.K., et al. A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies. Clin Cancer Res 2009, 15(November (22)):7085-7091. [Epub 2009 Nov 10].
256. Kupperman E., Lee E.C., Cao Y., et al. Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. Cancer Res 2010, 70(March (5)):1970-1980. [Epub 2010 Feb 16].
257. Damaj G., Lefrere F., Delarue R., et al. Thalidomide therapy induces response in relapsed mantle cell lymphoma. Leukemia 2003, 17:1914-1915.
258. Kaufmann H., Raderer M., Wohrer S., et al. Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma. Blood 2004, 104:2269-2271.
259. Wang M., Oki Y., Pro B., et al. Phase II study of Yttrium 90 (90Y) Ibritumomab Tiuxetan Zevalin®) in patients with relapsed and refractory Mantle Cell Lymphoma (MCL). Blood 2006, 108:2714.
260. Cruczman M.S., Reeder C.B., Polikoff J., et al. International study of lenalidomide in relapsed/refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 2008, 26. [May 20 suppl; abstr 8509].
261. Wiernik P.H., Lossos I.S., Tuscano J.M., et al. Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 2008, 26:4952-4957.
262. Habermann T.M., Lossos I.S., Justice G., et al. Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol 2009, 145:344-349.
263. Zinzani P.L., Witzig T.E., Vose J.M., et al. Confirmation of the efficacy and safety of lenalidomide oral monotherapy in patients with relapsed or refractory mantle-cell lymphoma: results of An International Study (NHL-003). ASH Annual Meet Abstr 2008, 112:262.
264. Witzig T.E., Geyer S.M., Ghobrial I., Phase II, et al. trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 2005, 23:5347-5356.
265. Ansell S.M., Inwards D.J., Rowland K.M., et al. Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group. Cancer 2008, 113:508-514.
266. Hess G., Herbrecht R., Romaguera J., et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009, 27:3822-3829.
267. Kouroukis C.T., Belch A., Crump M., et al. Flavopiridol in untreated or relapsed mantle-cell lymphoma: results of a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003, 21:1740-1745.
268. Lin T.S., Blum K.A., Fischer D.B., et al. Flavopiridol, fludarabine, and rituximab in mantle cell lymphoma and indolent B-cell lymphoproliferative disorders. J Clin Oncol 2010, 28:418-423.
269. Holman P., Medina B., Corringham S., et al. Early and robust immune responses to idiotype (Id) vaccination occur in mantle cell lymphoma (MCL) and indolent lymphoma (IL) patients following autologous stem cell transplantation (ASCT). Blood 2003, 102:899a.
270. Leonard J.P., Vose J., Timmerman J., Leonard J.P., Vose J., Timmerman J., et al. Recombinant idiotype-KLH vaccination (MyVaxTM) following CHOP chemotherapy in mantle cell lymphoma. Blood 2003, 102-5.
271. Neelapu S.S., Kwak L.W., Kobrin C.B., et al. Vaccine-induced tumor-specific immunity despite severe B-cell depletion in mantle cell lymphoma. Nat Med 2005, 11:986-991.